2018

  • Construction of the production facilities for subsidiary OP NanoPharma Co., Ltd was completed, marking the beginning of use of Nano-particle Micellar Delivery Technology to produce anti-cancer injectable solutions and powders

2017

  • OEP obtained letter of approval from Taiwan Food and Drug Administration for human organ bank
  • A subsidiary was established in Indonesia, expanding the Southeast Asian market
  • Vietnam office was restructured into a subsidiary of OEP

2016

  • The first anti-hyperlipidemia drug developed by OEP was officially launched in Taiwan
  • OEP signed a cooperative agreement with American company TissueTech, acquiring exclusive rights for the next series of ophthalmologic tissue products in Asia Pacific and stepping into the field of regenerative medicine
  • OEP entered a cooperative agreement with Second Sight, acquiring exclusive distribution rights for the Argus II Retinal Prosthesis System in Taiwan and entering the field of ophthalmology

2014

  • Orient PHARMA Co., Ltd had its first ANDA approved by US FDA, officially entered US market

2013

  • Signed agreement with Japan’s NanoCarrier Co., Ltd. to develop new cancer drug and construct a new plant
  • Orient PHARMA Co., Ltd awarded US Food and Drug Administration Manufacturing Plant Inspection certification

2012

  • OEP established a professional dermo-cosmetics sales team in the Philippines, setting up its dermo-cosmetics business in overseas market for the first time
  • Orient PHARMA Co., Ltd awarded Japan’s official foreign pharmaceutical manufacturer certification
  • Orient PHARMA Co., Ltd officially listed for OTC trading (Stock Code: 4166)

2011

  • Orient PHARMA Co., Ltd awarded Taiwan’s Food and Drug Administration PIC/S GMP certification

2010

  • Established office in Vietnam, enhancing Southeast Asian channels

2008

  • “Karihome” series marketed in China, which Established subsidiary company, Orient PHARMA Co., Ltdwas the first product of OEP entering China market
  • Established subsidiary company, Orient PHARMA Co., Ltd

2004

  • “Karihome” series marketed in Hong Kong, which was the milk powder business entering overseas market for the first time

2003

  • Imported Swedish injectable hyaluronic acid products, becoming the first company in Taiwan to obtain government permit for brands with hyaluronic acid
  • Officially listed for OTC trading (Stock Code: 4120)

2002

  • Established new offices in Philippines, further expanding the Company’s Southeast Asian territory
  • Established the Dermo-cosmetics Division and entered the skincare market

1999

  • OEP began deploying its overseas channels in Singapore, Malaysia, and Hong Kong, entering the Southeast Asian markets with prescription medicines
  • Invested in the GMP pharmaceutical plant and medical R&D

1989

  • Imported infant goat formula from New Zealand, and created the first private brand “Karihome” for domestic sales in Taiwan

1982

  • Founded Orient EuroPharma Co., Ltd and marketed prescription medicines

Honor

2018

  • The subsidiary in Singapore was ranked 88th in the 2015 and 2016 Top 100 Taiwanese Business in ASEAN for revenue and profit growth

2017

  • Ranked 484th among the top thousand large enterprises named by the CommonWealth Magazine

2016

  • Ranked 508th among the top thousand large enterprises named by the CommonWealth Magazine

2015

  • Ranked 85th among the top hundred companies which the new generation of Taiwan most long for
  • Orient EuroPharma Co., Ltd was named again as one of Benchmark Pharmaceutical Company (Bio Taiwan Highlight) By IBMI (Institute for Biotechnology and Medicine Industry)
  • Ranked 526th among the top thousand large enterprises named by the CommonWealth Magazine

2014

  • Orient EuroPharma Co., Ltd achieved class A+ for the 11th annual Information Enclosure Evaluation
  • Ranked 538th among the top thousand large enterprises named by the CommonWealth Magazine

2013

  • Orient EuroPharma Co., Ltd named as one of the top three benchmark biotechnology by the Institute for Biotechnology and Medicine Industry
  • Orient EuroPharma Co., Ltd achieved class A+ for the 10th annual Information Enclosure Evaluation
  • Ranked 549th among the top thousand large enterprises named by the CommonWealth Magazine

2012

  • Ranked 600th among the top thousand large enterprises named by the CommonWealth Magazine

2011

  • Honored with the 1st Gre Tai Securities Market Golden Laurel Award for excellent and sustainable enterprise
  • Orient EuroPharma Co., Ltd achieved class A+ for the 8th annual Information Enclosure Evaluation

2010

  • Orient EuroPharma Co., Ltd achieved class A+ for the 7th annual Information Enclosure Evaluation

2007

  • Orient EuroPharma Co., Ltd achieved class A+ for the 4th annual Information Enclosure Evaluation